Clinical trial
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With…
NCT00234403 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00234403 |
|---|---|
| Title | A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer |
| Official title | A Phase II Trial to Evaluate the Combination of ZD1839 (Iressa) and Fulvestrant (Faslodex®) in Patients With Advanced or Metastatic Breast Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | gefitinib and fulvestrant |
| Enrollment | 60 |
| Start date | May 1, 2004 |
| Completion | Oct 1, 2007 |
| First posted | Oct 7, 2005 |
| Last update posted | Apr 23, 2009 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: